Sun Pharma Q1 FY26 results show revenue up 9.5% year-on-year to ₹13,851 crore, but net profit fell 20% to ₹2,279 crore due to a one-time exceptional charge of ₹818 crore. US formulations and global business delivered steady, though moderate growth. EBITDA up 19.2% with margin improvement to 31.1%
Q1 FY26 Financial Overview
- Revenue: ₹13,851 crore, up 9.5% YoY
- Net Profit: ₹2,278 crore, down 19.6% YoY
- EBITDA: ₹4,302 crore, up 19.2% YoY
- EBITDA Margin: Improved to 31.1% from 28.5%
- India Formulations: ₹4,721 crore, up 13.9%
- US Formulations: $473 million, up 1.4%
- Global Innovative Medicines: $311 million, up 16.9%
Key Announcements
- LEQSELVI Launch in the US: A new treatment for severe alopecia areata, strengthening Sun’s dermatology and innovative portfolio
- 5 New Product Launches in India
- R&D Spend: ₹902.9 crore, 6.5% of sales
- Exceptional Item Impact: ₹818 crore one-time cost dragged down net profit
Retail Investor Takeaways
- Margin pressure in FY26 due to launch costs
- Regulatory clarity on US tariffs
- Performance of new launches like LEQSELVI